{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:21Z","timestamp":1791765381281,"version":"4.3.4"},"reference-count":61,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Research Project of Affiliated Hospital of North Sichuan Medical College","award":["2020ZD012"],"award-info":[{"award-number":["2020ZD012"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The purpose of this study is to assess the efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease (PAD) after endovascular therapy (EVT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of all studies reporting the outcomes of cilostazol after femoropopliteal EVT of PAD up to September 2022. Clinical outcomes of interest included primary patency, in-stent restenosis (ISR), vessel re-occlusion, freedom from target lesion revascularization (TLR), repeat revascularization, all-cause mortality, amputation, major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs), and bleeding complication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 4 randomized controlled trials (RCTs) and 8 observational studies containing a total of 4898 patients met the inclusion criteria and were included in this systematic review and meta-analysis. We found that the use of cilostazol was associated with higher primary patency after femoropopliteal artery EVT (odds ratio [OR]=1.67, 95% confidence interval [CI]=1.50-1.87, p&lt;0.001, I\n                      <jats:sup>2<\/jats:sup>\n                      =33.2%), a lower risk of ISR (OR=0.43, 95% CI=0.29-0.63, p&lt;0.001, I\n                      <jats:sup>2<\/jats:sup>\n                      =37.6%), repeat revascularization (OR=0.43, 95% CI=0.24-0.76, p&lt;0.005, I\n                      <jats:sup>2<\/jats:sup>\n                      =27.4%), and vessel re-occlusion (OR=0.59, 95% CI=0.38-0.93, p&lt;0.05, I\n                      <jats:sup>2<\/jats:sup>\n                      =0%). There was an increase in freedom from TLR rate (OR=2.19, 95% CI=1.58-3.05, p&lt;0.001, I\n                      <jats:sup>2<\/jats:sup>\n                      =0%), as well as a reduction in the occurrence of MALEs (OR=0.50, 95% CI=0.29-0.85, p&lt;0.05, I\n                      <jats:sup>2<\/jats:sup>\n                      =0%). However, there was no significant difference in amputation, MACEs, all-cause mortality, and major bleeding complications. Subgroup analysis showed that cilostazol treatment in patients with femoropopliteal drug-eluting stents (DES) implantation remained associated with higher primary patency and a lower risk of ISR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>After EVT of femoropopliteal artery lesions, additional oral cilostazol enhances primary patency, reduces the occurrences of ISR and vessel re-occlusion, diminishes the risks associated with MALEs, lowers the need for repeat revascularization, and increases freedom from TLR rates. However, it does not impact amputation, MACEs, all-cause mortality, or major bleeding complications. These findings suggest cilostazol as a potentially safe and effective adjunct therapy in patients with femoropopliteal PAD after EVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>After undergoing endovascular therapy (EVT) for femoropopliteal artery lesions, the addition of cilostazol to antiplatelet therapy can significantly improve primary patency, reducing the incidence of in-stent restenosis, repeat revascularization, vessel re-occlusion, and major adverse limb events while increasing freedom from target lesion revascularization rate. The simultaneous use of drug-eluting stents in the femoropopliteal artery lesions, combined with cilostazol, potentially results in a synergistic anti-stenotic effect. This therapeutic approach does not appear to be associated with an increased risk of major bleeding events or all-cause mortality. These findings provide additional evidence supporting the treatment of anti-stenosis in patients with femoropopliteal artery lesions after EVT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028241241248","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:30:50Z","timestamp":1712633450000},"page":"1872-1888","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Systematic Review and Meta-Analysis of Efficacy and Safety of Cilostazol Prescription in Patients With Femoropopliteal Peripheral Artery Disease After Endovascular Therapy"],"prefix":"10.1177","volume":"32","author":[{"given":"Qiang","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Dazhou Central Hospital, Dazhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyao","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5659-2869","authenticated-orcid":false,"given":"Jianghua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.101082"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.07.059"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.689141"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1583\/08-2461.1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602819895996"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.01.080"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666191122123855"},{"issue":"6","key":"e_1_3_3_10_2","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown T","year":"2021","unstructured":"Brown T, Forster RB, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021;6(6):CD003748.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339238"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.02.062"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.09.020"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602818771358"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2017.05.029"},{"key":"e_1_3_3_17_2","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12928-019-00602-z"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000711"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.69.1256"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.01.007"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/MDER.S21629"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.23304"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003319714551361"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602817719284"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2016.10.098"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270992"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2013.11.096"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000154"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003319715604768"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X19838327"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2020.08.125"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009338940"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602815619409"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.08.018"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1583\/11-3581.1"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-1029"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.06.010"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0711-8"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.16-332"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850067"},{"issue":"3","key":"e_1_3_3_44_2","first-page":"76","article-title":"Randomized angiographic and intravascular ultrasound comparison of dual-antiplatelet therapy vs triple-antiplatelet therapy to reduce neointimal tissue proliferation in diabetic patients","volume":"29","author":"Zuliani Mauro MF","year":"2017","unstructured":"Zuliani Mauro MF, Mangione JA, Costa JRJr, et al. Randomized angiographic and intravascular ultrasound comparison of dual-antiplatelet therapy vs triple-antiplatelet therapy to reduce neointimal tissue proliferation in diabetic patients. J Invasive Cardiol. 2017;29(3):76\u201381.","journal-title":"J Invasive Cardiol"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060938"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0364-3"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.15.2683"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70094-2"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004424-199509000-00004"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90062-0"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-007-9001-1"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2005.09.007"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250100593"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.07.087"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001195"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.12.1942"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.557359"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-014-1090-5"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018184"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07187-x"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4167"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.11.067"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028241241248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028241241248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028241241248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:04:10Z","timestamp":1779008650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028241241248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/15266028241241248"],"URL":"https:\/\/doi.org\/10.1177\/15266028241241248","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}